The present invention relates to a pharmaceutical tramadol composition for ophthalmic use. The composition is characterized in that it contains tramadol in a low concentration, specifically between 0.02% and 0.09%, and in that it is highly efficient in the treatment of ocular pain, for example following injuries or ocular surgery, or the ocular pain associated with dry eye syndrome.